Neoadjuvant PD1/PD-L1 Blockade Combined with Chemotherapy Associated with High Resectability and Pathological Responses in Borderline Resectable or Unresectable Stage III NSCLC By Ogkologos - June 3, 2025 215 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a multicentre cohort study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint... February 1, 2023 Keeping progress in oncology on the agenda: ESMO honours recipients of... December 3, 2020 Cancer in My Community: Accessing Care Through the Public Health System... May 9, 2023 6-Yr-Old With Cerebral Palsy Receives Dream Gift After Learning To Walk. January 9, 2020 Load more HOT NEWS Embedding research integrity at the core of our science Pan-FGFR Tyrosine Kinase Inhibitor Treatment Is Less Effective in Patients with... Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to... Ground-breaking trial pilots new tests to detect lung cancer earlier
